Business Description
Alaunos Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98973P1012
Share Class Description:
FRA:WEK: Ordinary SharesDescription
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.77 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -370.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -72.4 | |||||
| 3-Year EPS without NRI Growth Rate | -69.1 | |||||
| 3-Year FCF Growth Rate | -81.1 | |||||
| 3-Year Book Growth Rate | -64.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 89.73 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -56.14 | |||||
| 12-1 Month Momentum % | -22.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.3 | |||||
| Quick Ratio | 4.3 | |||||
| Cash Ratio | 2.04 | |||||
| Days Sales Outstanding | 152.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -123633.33 | |||||
| Net Margin % | -196350 | |||||
| FCF Margin % | -180033.33 | |||||
| ROE % | -187.01 | |||||
| ROA % | -140.36 | |||||
| ROIC % | -364.81 | |||||
| ROC (Joel Greenblatt) % | -600.03 | |||||
| ROCE % | -182.01 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 471.5 | |||||
| PB Ratio | 1.11 | |||||
| Price-to-Tangible-Book | 1.11 | |||||
| EV-to-EBIT | 0.26 | |||||
| EV-to-EBITDA | 0.26 | |||||
| EV-to-Revenue | -507 | |||||
| EV-to-FCF | 0.26 | |||||
| Price-to-Net-Current-Asset-Value | 1.11 | |||||
| Price-to-Net-Cash | 3.53 | |||||
| Earnings Yield (Greenblatt) % | 384.62 | |||||
| FCF Yield % | -389.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alaunos Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.006 | ||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 85.66 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.073571 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | -22.18 | ||
| 52-Week Range (€) | 1.41 - 4.7 | ||
| Shares Outstanding (Mil) | 215.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alaunos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alaunos Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alaunos Therapeutics Inc Frequently Asked Questions
What is Alaunos Therapeutics Inc(FRA:WEK)'s stock price today?
The current price of FRA:WEK is €1.41. The 52 week high of FRA:WEK is €4.70 and 52 week low is €1.41.
When is next earnings date of Alaunos Therapeutics Inc(FRA:WEK)?
The next earnings date of Alaunos Therapeutics Inc(FRA:WEK) is 2025-02-14 Est..
Does Alaunos Therapeutics Inc(FRA:WEK) pay dividends? If so, how much?
Alaunos Therapeutics Inc(FRA:WEK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers